Tanomastat (CAS 179545-77-8)
QUICK LINKS
Tanomastat, a readily available compound, serves as a non-peptidic inhibitor targeting matrix metalloproteinase-2 (MMP-2), MMP-3, and MMP-9 (with Kis values of 11, 143, and 301 nM, respectively). Referred to as BAY 12-9566 in scientific circles, Tanomastat represents a biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) that exhibits the potential for antineoplastic activity. By inhibiting MMP-2, MMP-3, and MMP-9, Tanomastat effectively suppresses extracellular matrix degradation. This inhibition carries the potential to impede processes such as angiogenesis, tumor growth, invasion, and metastasis. It is important to note that MMPs encompass a family of at least 18 zinc-containing endo-proteinases responsible for collagen and proteoglycan degradation
Tanomastat (CAS 179545-77-8) References
- Gateways to clinical trials. | Bayés, M., et al. 2005. Methods Find Exp Clin Pharmacol. 27: 331-72. PMID: 16082422
- Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. | Auranen, A. and Grénman, S. 2008. Int J Gynecol Cancer. 18 Suppl 1: 44-6. PMID: 18336400
- Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. | Chaudhary, AK., et al. 2013. Mutat Res. 753: 7-23. PMID: 23370482
- Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. | Wong, MS., et al. 2013. Clin Exp Pharmacol Physiol. 40: 307-19. PMID: 23534409
- Effects of azithromycin and tanomastat on experimental bronchiolitis obliterans. | Krenn, K., et al. 2015. J Thorac Cardiovasc Surg. 149: 1194-202. PMID: 25595376
- Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. | Winer, A., et al. 2018. Mol Cancer Ther. 17: 1147-1155. PMID: 29735645
- Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy. | Liang, M., et al. 2021. Transl Oncol. 14: 101221. PMID: 34530193
- Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies. | Liguori, NR., et al. 2021. Front Pharmacol. 12: 747180. PMID: 34531756
- Enhanced single-cell RNA-seq workflow reveals coronary artery disease cellular cross-talk and candidate drug targets. | Ma, WF., et al. 2022. Atherosclerosis. 340: 12-22. PMID: 34871816
- Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? | Verhulst, E., et al. 2022. Cancers (Basel). 14: PMID: 35158891
- Reviving the use of inhibitors of matrix metalloproteases in spinal cord injury: a case for specificity. | Ahmed, Z. 2023. Neural Regen Res. 18: 1925-1930. PMID: 36926709
- Recent advances in targeted therapy for pancreatic adenocarcinoma. | Fang, YT., et al. 2023. World J Gastrointest Oncol. 15: 571-595. PMID: 37123059
- Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article. | Singh, H. 2023. Glob Med Genet. 10: 79-86. PMID: 37228871
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tanomastat, 5 mg | sc-208416 | 5 mg | $311.00 |